AI translate
Acknowledgements Privacy Policy Cookie Policy How Can We Help? Go to the 2022 edition

ADA 2023

Medfyle Conference Coverage

ADA 2023 Medfyle

Conference Coverage

This activity is supported by educational grants from LILLY and NOVO NORDISK A/S.

Welcome

The American Diabetes Association’s 83rd Scientific Sessions took place in San Diego from 23-26, June 2023, and we are delighted to announce the return of the official ADA program. This free resource features a selection of interviews, key presentation summaries, with an overview of the data, plus commentaries and insight from leading experts in the field.

Vivian Fonseca, MD
ADA 2023 Medfyle Conference Coverage Editor

MedfyleToday

MedfyleToday - your fast-track to daily conference highlights directly from the American Diabetes Association’s 83rd Scientific Sessions® in San Diego. Our team was on site to bring you top picks from the ADA 2023 Scientific Sessions. Each day we showcased speaker interviews and a selection of highlights from key talks, combined with personal insights and commentaries on how new data impacts the diabetes landscape.

play-circle

Day 1

June
23
play-circle

Day 2

June
24
play-circle

Day 3

June
25
play-circle

Day 4

June
26

Interviews

Watch the interviews with some of the international experts who contributed to the American Diabetes Association’s 83rd Scientific Sessions.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Deep Dives

Interested in learning more about the latest advancements in current, emerging, and novel therapies for T2D, as well as new data on weight-centric management?

Oral Presentations

Missed the full presentation? Read at-a-glance summaries from a selection of oral presentations. Don’t forget to download the slides!

T2D & Obesity

Tirzepatide for treating obesity in type 2 diabetes

W. Timothy Garvey, MD, MACE; Matthias Tschöp, MD; Juan Pablo Frias, MD; Naveed Sattar, MD, PhD; Ildiko Lingvay, MD, MPH, MSCS

In adults with obesity and type 2 diabetes, 72 weeks of treatment with tirzepatide 10 mg and 15 mg once weekly led to substantial and clinically meaningful reduction in body weight.

ADA 2023 - Symposium 

SURMOUNT 2 Trial Results and Potential Role of Tirzepatide in Treating Obesity in Type 2 Diabetes

Read more

01-tirzepatide-for-treating-obesity-in-type2diabetes
T2D & Obesity

Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes

Ildiko Lingvay, MD, MPH, MSCS; Vanita Aroda, MD; Filip Knop, MD, PhD; Julio Rosenstock, MD; Sue Pedersen, MD, FRCPC; Sean Wharton MD, PharmD

OASIS: in adults without type 2 diabetes with overweight or obesity, once daily oral semaglutide 50 mg led to superior and clinically meaningful decrease in body weight vs. placebo. PIONEER PLUS: in adults with inadequately controlled type 2 diabetes oral semaglutide 25 mg and 50 mg were superior to 14 mg in reducing HbA1c and body weight.

ADA 2023 - Symposium 

Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trial

Read more

02-oral-semaglutide-for-treatment-of-obesity-and-type2diabetes
T2D & ASCVD

COORDINATE - Diabetes Study: a coordinated, multifaceted intervention for adults with T2D and atherosclerotic cardiovascular disease

Jennifer Green, MD; Neha Pagidipati, MD, MPH; Adam Nelson, MBBS, MBA, MPH, PhD; Christopher Granger, MD, FACC, FAHA; Ildiko Lingvay, MD, MPH, MSCS; Mikhail N Kosiborod, MD

In adults with T2D and atherosclerotic cardiovascular disease, a coordinated, multifaceted intervention increases the prescription of evidence-based therapies (high-intensity statins, ACEIs/ARBs, and SGLT2is /GLP-1 RAs).

ADA 2023 - Symposium 

COORDINATE - Diabetes Study Results

Read more

03-coordinate-diabetes-study-a-coordinated-multifaceted-intervention-for-adults-with-t2d-and-atherosclerotic-cardiovascular-disease
See all

Poster Presentations

Read at-a-glance summaries from a selection of poster presentations.

T2D Therapy

Once-weekly insulin icodec provides superior glycemic control over once-daily basal insulin

Harpreet S Bajaj, MD, MPH

Insulin icodec with a dosing guide app is superior in HbA1C reduction with low hypoglycemia rates vs. once daily basal insulin analogs in a real-world setting.

ADA 2023 - Poster Session

Superior Glycemic Control with Once-Weekly Insulin Icodec with a Dosing Guide App vs. Once-Daily (OD) Basal Insulin Analogs in Insulin-Naïve T2D—ONWARDS 5

Read more

p01-once-weekly-insulin-icodec-provides-superior-glycemic-control-over-once-daily-basal-insulin
T2D Therapy

Once weekly insulin icodec vs. insulin glargine U100

Julio Rosenstock, MD

Once weekly insulin icodec significantly improves time in range and time above range compared to insulin glargine U100 with no difference in hypoglycemia.

ADA 2023 - Poster Session

CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1

Read more

p02-once-weekly-insulin-icodec-vs-insulin-glargine-u100
T2D & Obesity

Orforglipron vs. placebo and dulaglutide in type 2 diabetes

Juan P. Frias, Stanley H. Hsia, Sarah Eyde, Rong Liu, Xiaosu Ma, Manige Konig, Christof M. Kazda, Edward J. Pratt, Kieren J. Mather, Axel Haupt, Deborah A. Robins

Orforglipron is an oral GLP-1 RA under development for type 2 diabetes and weight loss. This trial showed that this new drug led to significant decreases in HbA1c and body weight with a safety profile consistent with other GLP-1 RAs.

ADA 2023 - Poster Session

Effect of Orforglipron vs. Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes

Read more

p03-orforglipron-vs-placebo-and-dulaglutide-in-type-2-diabetes
See all
About ADA Feedback

DOWNLOAD THE APP

Enhance your clinical practice with just five minutes of learning, staying up to date with the latest medical research and essential knowledge.


Or visit medfyle.com

Ask the Expert

Have a question? Submit it below.
A selection of the most interesting questions will be answered in a new video. You will receive an email when answers will be published.